Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients

被引：0
|
作者：
Marit A. C. Vermunt
Merel van Nuland
Lisa T. van der Heijden
Hilde Rosing
Jos. H. Beijnen
Andries M. Bergman
机构：
[1] The Netherlands Cancer Institute,Department of Pharmacy and Pharmacology
[2] The Netherlands Cancer Institute,Department of Medical Oncology
[3] Utrecht University,Department of Pharmaceutical Sciences
[4] Modra Pharmaceuticals B.V.,Department of Oncogenomics
[5] The Netherlands Cancer Institute,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2022年 / 89卷
关键词：
Docetaxel; Pharmacokinetics; Metastatic castration-resistant prostate cancer; Metastatic hormone-sensitive prostate cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：785 / 793
页数：8
相关论文
共 50 条
  • [1] Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients
    Vermunt, Marit A. C.
    van Nuland, Merel
    van der Heijden, Lisa T.
    Rosing, Hilde
    Beijnen, Jos H.
    Bergman, Andries M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (06) : 785 - 793
  • [2] Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Schweizer, Michael T.
    Gulati, Roman
    Mostaghel, Elahe A.
    Nelson, Peter S.
    Montgomery, R. Bruce
    Yu, Evan Y.
    Cheng, Heather H.
    MEDICAL ONCOLOGY, 2016, 33 (07)
  • [3] Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Michael T. Schweizer
    Roman Gulati
    Elahe A. Mostaghel
    Peter S. Nelson
    R. Bruce Montgomery
    Evan Y. Yu
    Heather H. Cheng
    Medical Oncology, 2016, 33
  • [4] Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer
    Mager, Rene
    Savko, Olga
    Boehm, Katharina
    Thomas, Anita
    Dotzauer, Robert
    Borgmann, Hendrik
    Jaeger, Wolfgang
    Thomas, Christian
    Haferkamp, Axel
    Hoefner, Thomas
    Tsaur, Igor
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (12) : 999 - 1005
  • [5] Darolutamide in hormone-sensitive and castration-resistant prostate cancer
    Palmieri, Valeria Emma
    Roviello, Giandomenico
    D'Angelo, Alberto
    Casadei, Chiara
    De Giorgi, Ugo
    Giorgione, Roberta
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (05) : 535 - 544
  • [6] Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document
    Lapini, Alberto
    Caffo, Orazio
    Pappagallo, Giovanni
    Iacovelli, Roberto
    D'Angelillo, Rolando Maria
    Vavassori, Vittorio
    Ceccarelli, Roberta
    Bracarda, Sergio
    Jereczek-Fossa, Barbara Alicja
    Da Pozzo, Luigi
    Conti, Giario Natale
    CANCERS, 2019, 11 (12)
  • [7] Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer
    Wang, Zhipeng
    Liu, Haoyang
    Zhu, Qiyu
    Chen, Junru
    Zhao, Jinge
    Zeng, Hao
    BMC CANCER, 2024, 24 (01)
  • [8] Docetaxel in the treatment of metastatic hormone sensitive and castration-resistant prostate cancer: A meta-analysis.
    Zhang, Shijia
    Sanchez, Larysa Jessica
    Liu, Jieqi
    Wang, Yucai
    Duma, Narjust
    Chang, Victor Tsu-Shih
    Alter, Robert S.
    Gutierrez, Martin
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer
    Tashiro, Kojiro
    Kimura, Shoji
    Tsuzuki, Shunsuke
    Urabe, Fumihiko
    Fukuokaya, Wataru
    Mori, Keiichiro
    Aikawa, Koichi
    Murakami, Masaya
    Sasaki, Hiroshi
    Miki, Kenta
    Miki, Jun
    Shimomura, Tatsuya
    Yamada, Hiroki
    Hata, Kenichi
    Nishikawa, Hideomi
    Abe, Hirokazu
    Watanabe, Ken
    Kimura, Takahiro
    CLINICAL GENITOURINARY CANCER, 2024, 22 (03)
  • [10] Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer
    Gschwend, Juergen E
    Miller, Kurt
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (01): : 41 - 49
12345